Mentions in press and media 4
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 29, 2026 | Novaspira Biotherapeutics Late-Breaking Oral Presentation of Phase 1 Data for a Novel GPC3x4-1BB Bispecific at SITC 2026 | NovaSpira Biotherapeutics Novaspira Biotherapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data for BOS-342 (NS-342), a Novel GPC3 × 4-1BB Bispecific at SITC 2026 CHATHAM, NJ, UNITED STATES, October 29, 2026 /EINPresswi... |
| Oct 12, 2026 | NovaSpira Announces FDA Acceptance of IND for NS - 342 in GPC3 Positive Tumors | NovaSpira Biotherapeutics Secures U.S. FDA Acceptance of IND Application for NS 342 in Advanced Hepatocellular Carcinoma and Other GPC3 Expressing Solid Tumors CHATHAM, NJ, UNITED STATES, October 12, 2026 /EINPresswire.com/ -- NovaSpira Bio... |
| Aug 31, 2026 | NovaSpira Receives MFDS Approval to Start Phase 1 Trial of NS 342 (GPC3x4-1BB Bispecific) in Advanced Solid Tumors | CHATHAM, NJ, UNITED STATES, August 31, 2026 /EINPresswire.com/ -- NovaSpira Biotherapeutics today announced that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has approved the company’s updated Phase 1 clinical trial ... |
Reviews 0
FAQ about NovaSpira Biotherapeutics
What has the press written about NovaSpira Biotherapeutics?
Parsers VC has collected 4 articles mentioning NovaSpira Biotherapeutics, among them “Novaspira Biotherapeutics Late-Breaking Oral Presentation of Phase 1 Data for a Novel GPC3x4-1BB Bispecific at SITC 2026” (Oct 29, 2026) and “NovaSpira Announces FDA Acceptance of IND for NS - 342 in GPC3 Positive Tumors” (Oct 12, 2026).
Is NovaSpira Biotherapeutics still active?
Yes, NovaSpira Biotherapeutics is active; its latest activity on Parsers VC dates from Nov 7, 2026.